• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Rep . Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19

tetano

Editor, Senior Moderator
Cell Rep


. 2022 Jun 13;111020.
doi: 10.1016/j.celrep.2022.111020. Online ahead of print.
Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19


Sai Preetham Peddireddy[SUP] 1 [/SUP], Syed A Rahman[SUP] 2 [/SUP], Anthony R Cillo[SUP] 3 [/SUP], Godhev Manakkat Vijay[SUP] 3 [/SUP], Ashwin Somasundaram[SUP] 3 [/SUP], Creg J Workman[SUP] 3 [/SUP], William Bain[SUP] 4 [/SUP], Bryan J McVerry[SUP] 4 [/SUP], Barbara Methe[SUP] 4 [/SUP], Janet S Lee[SUP] 4 [/SUP], Prabir Ray[SUP] 5 [/SUP], Anuradha Ray[SUP] 5 [/SUP], Tullia C Bruno[SUP] 3 [/SUP], Dario A A Vignali[SUP] 3 [/SUP], Georgios D Kitsios[SUP] 4 [/SUP], Alison Morris[SUP] 4 [/SUP], Harinder Singh[SUP] 6 [/SUP], Aniruddh Sarkar[SUP] 7 [/SUP], Jishnu Das[SUP] 8 [/SUP]



Affiliations

Abstract

While there have been extensive analyses characterizing cellular and humoral responses across the severity spectrum in COVID-19, outcome predictors within severe COVID-19 remain less comprehensively elucidated. Furthermore, properties of antibodies (Abs) directed against viral antigens beyond spike and their associations with disease outcomes remain poorly defined. We perform deep molecular profiling of Abs directed against a wide range of antigenic specificities in severe COVID-19 patients. The profiles included canonical (spike , receptor-binding domain [RBD], and nucleocapsid [N]) and non-canonical (orf3a, orf8, nsp3, nsp13, and membrane [M]) antigenic specificities. Notably, multivariate Ab profiles directed against canonical or non-canonical antigens are equally discriminative of survival in severe COVID-19. Intriguingly, pre-pandemic healthy controls have cross-reactive Abs directed against nsp13, a protein conserved across coronaviruses. Consistent with these findings, a model built on Ab profiles for endemic coronavirus antigens also predicts COVID-19 outcome. Our results suggest the importance of studying Abs targeting non-canonical severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and endemic coronavirus antigens in COVID-19.

Keywords: COVID-19; CP: Immunology; CP: Microbiology; antibody profiling; cross-reactivity; endemic coronaviruses; non-canonical antigens; nsp13; systems immunology.
 
Back
Top Bottom